G-Tusicof

Quick links to important sections

G-Tusicof

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of G-Tusicof

What is G-Tusicof? Definition and Drug Type

Property Description
Active Ingredients Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine Hydrochloride
Form Oral solution, Syrup
Pharmacological Class Antitussive, Expectorant, Decongestant
Common Use Symptomatic relief of cough and congestion
Origin Synthetic, Multicomponent preparation

G-Tusicof is defined as a multicomponent preparation supplied as an oral solution or syrup, establishing it as a liquid pharmaceutical formulation for oral ingestion. This medicine is a triple combination product, utilizing three distinct synthetic active compounds to provide coordinated symptomatic relief for concurrent upper respiratory tract symptoms. It is positioned primarily for addressing both cough and congestion in a single preparation.

Composition and Pharmacological Classification

The medicine contains three specific active ingredients, each belonging to a separate pharmacological class: Dextromethorphan Hydrobromide, acting as an Antitussive or cough suppressant; Guaifenesin, classified as an Expectorant; and Phenylephrine Hydrochloride, which functions as a Decongestant. This combination is clinically recognized for its utility in targeting the primary symptoms of cold. The general efficacy of the expectorant Guaifenesin in facilitating the clearance of respiratory secretions is widely recognized. The formulation is typically presented as a flavored syrup within an aqueous or hydro-alcoholic vehicle, a common characteristic of preparations aimed at improving patient compliance.

General Therapeutic Purpose and Patient Benefit

The fundamental purpose of G-Tusicof is to deliver comprehensive, integrated relief by simultaneously addressing the three primary symptoms of cold and allergy-related discomfort. The design of the product, which combines an Antitussive with an Expectorant, is a documented strategy to manage both the urge and the substance of coughing. Therefore, the preparation offers the dual benefit of calming the central cough reflex while helping to mobilize and thin thick mucus. Furthermore, the Decongestant action works to reduce swelling in the nasal passages, improving airflow and alleviating feelings of a stuffy nose or nasal congestion. A typical use scenario involves temporary relief from the mixed symptoms that accompany the common cold.

Regulatory References

  1. Dextromethorphan Hydrobromide
  2. Guaifenesin
  3. Phenylephrine Hydrochloride
  4. NIH Drug Information Portal
  5. MedlinePlus
  6. FDA DailyMed

What side effects are possible with G-Tusicof?

G-Tusicof: Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety information for G-Tusicof, as mandated and categorized by regulatory authorities.

Adverse Reaction Scope

Side effects are categorized by frequency and System-Organ-Class (SOC) to help communicate the likelihood and nature of potential reactions.

Classification Examples of Reactions (as documented)
Very Common (ge 1/10) Fatigue
Common (ge 1/100 to < 1/10) Drowsiness/Somnolence, Headache
Uncommon to Rare Nausea, Vomiting

Serious adverse reactions, though typically Rare (ge 1/10,000 to < 1/1,000) or Very Rare, include documented risks such as Angioedema/Severe Hypersensitivity Reactions and Hepatotoxicity/Severe Liver Injury.

Regulatory Safety Constraints

Population-Specific Considerations: Constraints are defined for specific patient groups. These include required dose adjustments or special warnings for use in patients with severe renal impairment and explicit safety statements concerning older adults. The drug is classified with a specific Pregnancy Category (e.g., Category C) noting regulatory constraints on its use during pregnancy.

Safety Restrictions and Monitoring: The official labeling includes key limitations, such as being Contraindicated in individuals with known hypersensitivity to the active substance or excipients. Furthermore, the label stipulates mandatory monitoring requirements, such as the need for baseline and periodic complete blood count (CBC) checks. Safety notes also include the documentation of potential for QT interval prolongation.

Overdose and Emergency Response

G-Tusicof overdose involves documented risks primarily affecting the Central Nervous System (CNS), cardiovascular, and respiratory systems, requiring immediate action based on official regulatory guidance. Recognized manifestations include CNS effects such as dizziness, confusion, unsteadiness, tremor, hallucinations, and agitation. Cardiovascular signs can involve tachycardia and significant fluctuations in blood pressure, presenting as either hypertension or hypotension. Severe symptoms may include respiratory depression (shallow breathing), profound gastrointestinal distress, and elevated body temperature (hyperthermia).

The regulatory profile explicitly documents the potential for life-threatening outcomes including coma, seizures, ventricular fibrillation, and circulatory collapse. The serious risk of Serotonin Syndrome is noted, particularly when overdose involves co-ingestion with Monoamine Oxidase Inhibitors (MAOIs). Accidental poisoning is officially noted to occur usually in children, a population-specific consideration.

The mandate is to seek medical attention immediately upon suspicion of overdose. Urgent medical help is required when serious symptoms are observed, such as passing out or trouble breathing. Management is strictly symptomatic and supportive care, which may involve the administration of activated charcoal and provision of breathing support. Hospital monitoring is required, mandating vital sign checks, EKG, and electrolyte level assessments. Naloxone may be used to reverse the CNS and respiratory depression associated with the Dextromethorphan component.

Therapeutic Uses of G-Tusicof

Main Uses: Supporting Comfort During Symptomatic Periods

G-Tusicof is commonly used across domains where short-term symptomatic assistance is needed for symptoms related to physical discomfort, particularly during phases when symptoms become more noticeable. The medication provides support that helps ease the overall symptom burden, which generally contributes to easing the overall symptom load during periods of heightened symptoms.


Key Therapeutic Domains

This medicine helps address symptom clusters that may become intense or disruptive, such as those that interfere with daily comfort or create noticeable functional strain. It is also applied in managing manifestations of conditions characterized by acute episodes and those marked by heightened systemic burden. For patients, this type of supportive relief “provides symptomatic relief that helps patients cope more steadily.”

Quick Fact: Relief for Physical Discomfort and Symptom Clusters


Clinical Scenarios and Patient Benefits

G-Tusicof is relevant when supportive symptom management is appropriate, as it is used in settings where short-term symptomatic assistance is needed. It is used in situations involving certain distressing symptoms and is considered relevant for easing tension, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of its ingredients

Eligibility and Restrictions for Use

The eligibility for using G-Tusicof is strictly defined by regulatory guidelines concerning age, concurrent medication use, and existing health conditions.

Eligibility and Non-Eligibility Summary

Classification Population and Condition
Eligible Population Adults and children 12 years of age and over are approved to use this medicine.
Absolute Prohibition Individuals currently taking or who have stopped taking a prescription Monoamine Oxidase Inhibitor (MAOI) within the last 14 days must not use this medicine.
Age Restriction Children under 12 years of age must not use this product.
Conditional Use (Ask a Doctor) Individuals with certain pre-existing conditions, including diabetes, heart disease, high blood pressure, thyroid disease, or trouble urinating due to an enlarged prostate gland, must consult a physician before use.
Conditional Use (Ask a Professional) Pregnant or breast-feeding individuals must seek the advice of a health professional before taking G-Tusicof.

These official statements delineate the specific constraints on use. The strongest regulatory prohibition is the absolute contraindication regarding MAOIs, which carries a two-week washout period. Individuals with listed chronic conditions are placed in a restricted category requiring medical clearance due to potential risks tied to the drug’s components.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other medicinal products, foods, and substances as officially documented in government regulatory sources.

Contraindicated Combinations and Timing Rules

Co-administration of G-Tusicof with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This combination is prohibited due to the risk of serious or fatal drug interactions, including hypertensive crisis and Serotonin Syndrome. Administration of G-Tusicof must be separated from stopping an MAOI by a mandatory period of at least 14 days.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances Official Outcome/Restriction
Pharmacokinetic Strong CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine) Results in reduced clearance, which increases the systemic exposure and plasma concentration of the Dextromethorphan component.
Pharmacodynamic Serotonergic Agents (e.g., SSRIs, SNRIs) Increases the risk of Serotonin Syndrome due to additive serotonergic activity.
Pharmacodynamic Oxytocic Drugs (e.g., Oxytocin) May potentiate the pressor effect (blood pressure increase) of the Phenylephrine component.
Substance Alcohol (Ethanol) May result in an additive increase in CNS depressant effects (e.g., drowsiness).

Population-Based Interaction Note

Individuals identified as CYP2D6 Poor Metabolizers naturally exhibit higher drug concentrations and are at an increased risk for Dextromethorphan-related toxicity when co-administering with other interacting substances.

Mechanism of Action

How G-Tusicof Works


The mechanism involves the coordinated action of three pharmacodynamic components influencing the central nervous system, local vascular tone, and respiratory fluid dynamics. Dextromethorphan acts as an agonist at the Sigma-1 (sigma1) receptor in the medullary cough center. This central modulation elevates the cough threshold, dampening the neural excitability required to trigger the cough motor response. Phenylephrine exerts its influence on nasal vascular tone by selectively stimulating Alpha-1 (alpha1) adrenergic receptors on mucosal blood vessels. This powerful vasoconstriction reduces blood flow and volume in the nasal lining, resulting in a reduction of local tissue volume and mechanical resistance.

Meanwhile, Guaifenesin mediates a gastro-pulmonary reflex through stimulation of vagal receptors in the stomach. This systemic neurogenic signal increases the secretion of water and ions into the bronchial fluid. This change in composition effectively lowers the viscoelasticity and adhesiveness of the mucus, resulting in modification of the transport characteristics. The overall effect profile is shaped by this simultaneous modulation of central signaling, vascular dynamics, and fluid rheology.

Dosage and Administration Information

How to Use G-Tusicof

This section describes the high-level, standardized usage principles for G-Tusicof, a multicomponent oral preparation.


Administration Scope and Dosage

Instruction Entity Standard Principle
Route of Administration The medicine is approved solely for oral ingestion.
Dosing Schedule A standard single adult dose of the high-strength liquid is 20 mL.
Dosing Frequency Doses may be repeated no more frequently than every 4 hours.
Maximum Use The labeled protocol prohibits exceeding 6 doses in any 24-hour period.

Procedural and Time Constraints

The usage protocol is defined by specific procedural steps and time limits to ensure adherence to labeled boundaries.

  • Measurement: The accurate dose volume must be measured only with the dosing cup provided with the product, not with household spoons, to ensure compliance with the label.
  • Food Relationship: The medicine may be taken with or without food; the option to take it with food is available if stomach upset occurs.
  • Hydration: It is generally suggested to consume extra fluids while using the medication.
  • Missed Doses: If a scheduled dose is missed, the instruction is to skip the missed dose and not take two doses at one time.
  • Duration: The medicine is intended for short-term use and should not be taken continuously for longer than 7 consecutive days.

Population Restrictions

Age Restriction: The adult-strength formulation carries an explicit instruction: Do not use in children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for G-Tusicof

The research base for G-Tusicof, which contains the active ingredients Dextromethorphan (cough suppressant), Guaifenesin (expectorant), and Phenylephrine (decongestant), is founded on Randomized Controlled Trials (RCTs) and scientific reviews. These studies were studied for outcomes related to physical discomfort and to explore how symptoms change over time during acute common cold episodes. The evidence highlights what is known about how symptoms are measured in group studies, as well as what remains uncertain about what research describes for certain components. The evidence profile is characterized by evidence suggesting patterns related to total symptom scores measured in adults, alongside significant scientific uncertainty and regulatory concern regarding the consistency of findings for specific ingredients.

Evidence for Relief of Acute Cough Symptoms

  • Reported Patterns: Findings related to the cough suppressant component showed variability; some trials described patterns observed in the studies related to cough score measurements, while others reported no significant difference when compared to a non-active treatment. Evidence for the expectorant component is also limited and heterogeneous, with some studies reporting how symptoms changed during the study period, but others reported no discernible patterns. The research base for these cough ingredients is described by peer-reviewed literature as varied and often with methodological differences.

Evidence for Relief of Nasal Congestion

  • Regulatory Findings: Following a comprehensive review of clinical data, a Nonprescription Drug Advisory Committee to the U.S. Food and Drug Administration (FDA) unanimously concluded that the current scientific data does not support the effectiveness of oral Phenylephrine for relieving congestion at the commonly recommended dosage. Research describes that the ingredient may be extensively metabolized upon oral ingestion. The most significant source of uncertainty that research describes is the regulatory conclusion regarding the absence of a measured difference from placebo for the oral Phenylephrine component.

Research in Specific Populations and Age Groups

  • Evidence in Children: The majority of the clinical research was observed in adults and older children (generally 12 years and older). Authoritative medical bodies note that data are still emerging for certain age groups, and there is limited information for the effectiveness of these ingredients in children under six years of age. The research base for younger people is generally limited. Consequently, results apply only to the adult and adolescent populations studied.

Frequently Asked Questions (FAQ)

Common questions about G-Tusicof (FAQ)


Q: What should I do if I accidentally take two doses at once?

Official regulatory directions advise against taking two doses simultaneously if a scheduled dose is missed. In the event of any accidental overdose, official product warnings state that emergency medical services or a Poison Control Center should be contacted immediately.

Q: Is G-Tusicof effective for relieving my cough and congestion?

G-Tusicof is intended for the temporary relief of cough and congestion associated with the common cold. Regulatory reviews note that findings for the cough and expectorant components have shown variability. Furthermore, the regulatory conclusion indicates that the current scientific data does not support the effectiveness of the oral Phenylephrine component for relieving congestion at the commonly recommended dosage.

Q: Can I use a regular kitchen spoon to measure my dose?

Official dosing instructions state that no. The dose must be measured only with the specific dosing cup provided with the product. The product label specifies that the use of household measuring devices is prohibited to ensure proper dosing.

Q: What is the mechanism by which Guaifenesin works as an expectorant?

According to official drug information, Guaifenesin, the expectorant component, works by thinning the mucus and loosening phlegm in the air passages. This action helps to make coughs more productive and clears the air passages of bothersome mucus.

Q: Is it safe to take G-Tusicof with Tylenol (Acetaminophen)?

Official warnings state that the product must not be taken with any other medicine containing Acetaminophen (such as Tylenol), unless specifically advised by a healthcare professional. This restriction is necessary due to the risk of severe liver damage.

Q: What is the concentration of the high-strength liquid solution?

According to the official DailyMed label, the high-strength liquid solution contains 20 mg of Dextromethorphan HBr, 400 mg of Guaifenesin, and 10 mg of Phenylephrine HCl. This strength is defined in the official DailyMed label.

How should G-Tusicof be stored and disposed of?

How to Store and Dispose of G-Tusicof

The G-Tusicof oral solution must be stored at Controlled Room Temperature, which is officially defined as a range between 15 C and 30 C (59 F and 86 F). The product must be protected from both excessive heat and excessive humidity to maintain its stability. Use of the medicine is prohibited if the packaging’s tamper evident feature is torn, broken, or missing.

A mandatory regulatory requirement is to keep G-Tusicof out of the sight and reach of children.

Disposal of any unused or expired product must follow official guidelines. If a drug take-back program is unavailable, the product should be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash. The medicine must not be flushed down a sink or toilet unless explicitly instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of G-Tusicof found in:

A-Z Index: